Drug Discovery Today

Article	Citations
Contents page 2	233
Contents page	215
Multiple strategies for the treatment of invasive breast carcinoma: A comprehensive prospective	190
Adjunctive therapy for multidrug-resistant bacterial infections: Type III secretion system and efflux inhibitors	190
Demystifying the potential of inhibitors targeting DNA topoisomerases in unicellular protozoan parasites	165
Achieving end-to-end success in the clinic: Pfizer’s learnings on R&D productivity	150
Opportunities and challenges in drug discovery targeting the orphan receptor GPR12	135
Double-edged sword: Therapeutic efficacy versus toxicity evaluations of doped titanium implants	126
The recent progress of deep-learning-based in silico prediction of drug combination	124
Dysbiosis versus diabesity: Pathological signaling and promising therapeutic strategies	120
CIPDB: A biological structure databank for studying cation and π interactions	113
Recent development in the design of small ‘drug-like’ and nanoscale glycomimetics against Escherichia coli infections	112
Tubulin targeting agents and their implications in non-cancer disease management	108
General aspects of powder rheology applied to pharmaceutical formulations	108
The potential value of 5-androstenediol in countering acute radiation syndrome	107
Redox active or thiol reactive? Optimization of rapid screens to identify less evident nuisance compounds	99
Mitochondrial dysfunction: A potential target for Alzheimer’s disease intervention and treatment	96
Models and approaches to comprehend and address glial inflammation following spinal cord injury	93
Development of JmjC-domain-containing histone demethylase (KDM2-7) inhibitors for cancer therapy	90
The global status of bioequivalence trials: a comprehensive clinical trial landscape analysis based on the Trialtrove database	87
Computational modeling approaches and regulatory pathways for drug combinations	86
Gastroretentive drug delivery systems: A holy grail in oral delivery	84
From promise to progress: the dynamic landscape of glioblastoma immunotherapy	83
Antibody–drug conjugates: What drives their progress?	80
Targeted drug delivery to the retinal pigment epithelium: Untapped therapeutic potential for retinal diseases	79

Generative AI: driving productivity and scientific breakthroughs in pharmaceutical R&D	77
Repurposing of parenterally administered active substances used to treat pain both systemically and locally	77
A global bibliometric and visualized analysis of bacteria-mediated cancer therapy	77
Advancing drug repurposing research: Trends, collaborative networks, innovation and knowledge leaders	76
Specificity of pharmacokinetic modeling of nanomedicines	76
Trends in oral small-molecule drug discovery and product development based on product launches before and after the Rule of Five	76
Exploration of small-molecule inhibitors targeting Hsp110 as novel therapeutics	74
Contents page 2	72
Recent advancements in mass spectrometry for higher order structure characterization of protein therapeutics	71
Advancing pharmacogenetics research in Africa: the “Project Africa GRADIENT” initiative	71
Randomized controlled trials do not always fit the purpose: A science-based response to Venetis and Mol’s editorial on biosimilars of follitropin alfa	71
Pathogenic TDP-43 in amyotrophic lateral sclerosis	70
Bridging informatics and medicinal inorganic chemistry: Toward a database of metallodrugs and metallodrug candidates	69
Metabolic reprogramming: Unveiling the therapeutic potential of targeted therapies against kidney disease	68
Towards Pharma 4.0 in clinical trials: A future-orientated perspective	67
Molecular approaches for the treatment and prevention of Friedreich's ataxia	67
Lipid- and polymer-based formulations containing TNF-α inhibitors for the treatment of inflammatory bowel diseases	64
Investigating miRNA subfamilies: Can they assist in the early diagnosis of acute myocardial infarction?	63
PD-L1 small-molecule modulators: A new hope in epigenetic-based multidrug cancer therapy?	62
MTHFD2: A significant mitochondrial metabolic enzyme and a novel target for anticancer therapy	62
Systematic review and QSPR analysis of chemical penetration through the nail to inform onychomycosis candidate selection	59
The main aspects of non-clinical studies required for obtaining marketing authorisation for small molecules and biologics/biopharmaceuticals in the European Union and the United States	58
Steps toward nebulization in-use studies to understand the stability of new biological entities	58
MRI assessment of cerebral perfusion in clinical trials	58
Caught between a ROCK and a hard place: current challenges in structure-based drug design	55
Master protocols and other innovative trial designs in inflammation and immunology to expedite clinical drug development	55
Mutation informatics: SARS-CoV-2 receptor-binding domain of the spike protein	54
Medicinal chemistry aspects of uracil containing dUTPase inhibitors targeting colorectal cancer	54
Targeting mutant EGFR in non-small cell lung cancer in the context of cell adaptation and resistance	54
Targeted protein degradation: current molecular targets, localization, and strategies	54
Recent advances towards overcoming the blood–brain barrier	54
Unlocking therapeutic frontiers: harnessing artificial intelligence in drug discovery for neurodegenerative diseases	54
Translational PK/PD: a retrospective analysis of performance and impact from a drug portfolio	54
ImmunoPET imaging of hematological malignancies: From preclinical promise to clinical reality	52
Role of siRNA-based nanocarriers for the treatment of neurodegenerative diseases	52
Overcoming the protein corona in chitosan-based nanoparticles	52
Embryonic and larval zebrafish models for the discovery of new bioactive compounds against tuberculosis	51
Lactose in tablets: Functionality, critical material attributes, applications, modifications and co-processed excipients	51
Oral delivery of nucleic acid therapeutics: Challenges, strategies, and opportunities	51
Triple-negative breast cancer brain metastasis: An update on druggable targets, current clinical trials, and future treatment options	51
The emerging role of fatty acid binding protein 7 (FABP7) in cancers	50
Organoids in modelling infectious diseases	50
A review on the recent advances of interaction studies of anticancer metal-based drugs with therapeutic targets, DNA and RNAs	49
Overview of new indications for novel drugs approved in China between 2018 and 2024	48
Global or local: The future of biotech	48
Opioid epidemic and the urge to discover new treatment options	48
Recent advances in Clp protease modulation to address virulence, resistance and persistence of MRSA infection	48
50 shades of AI in regulatory science	48
Genetic–epigenetic targets for PCOS-associated diabesity	47
Recent advances in multitarget-directed ligands via in silico drug discovery	47

Illuminating function of the understudied druggable kinome	47
Review of the impact of the FDA’s Fast Track Designation on biotechnology companies’ share prices	47
Drugs from drugs: New chemical insights into a mature concept	46
Recent advances in dual-drug co-amorphous systems	46
Self-amplifying mRNA vaccines: Mode of action, design, development and optimization	45
Regulatory readiness to facilitate the appropriate use of innovation in clinical trials: The case of decentralized clinical trial approaches	45
Contents page	45
Hippo signaling in acute kidney injury to chronic kidney disease transition: Current understandings and future targets	44
Potential nanocarrier-mediated miRNA-based therapy approaches for multiple sclerosis	44
Elevating life science R&D success with AI: a framework	44
Back on the scene: Advances and challenges in CD3-related drugs in tumor therapy	44
In silico resources help combat cancer drug resistance mediated by target mutations	43
Decentralised, patient-centric, site-less, virtual, and digital clinical trials? From confusion to consensus	43
An overview of progress in human metapneumovirus (hMPV) research: Structure, function, and therapeutic opportunities	43
The role of gut microbial β-glucuronidase in drug disposition and development	43
Cubosome-based cosmeceuticals: A breakthrough in skincare	42
Advancements and challenges in using AI for biomarker detection in early Alzheimer’s disease	41
Pharmaceutical strategies for the treatment of bacterial biofilms in chronic wounds	41
Sustainability by design for recombinant protein therapeutics	41
Open innovation: A paradigm shift in pharma R&D?	41
Impact of HDAC inhibitors on macrophage polarization to enhance innate immunity against infections	40
Vaginal drug delivery system: A promising route of drug administration for local and systemic diseases	39
CPPsite3: An updated large repository of experimentally validated cell-penetrating peptides	39
Recent insights into viral infections as a trigger and accelerator in alzheimer's disease	39
IRE1α-mediated UPR activation in gastrointestinal cancers: Adaptive mechanisms and therapeutic potential	39
UCP1 activation: Hottest target in the thermogenesis pathway to treat obesity using molecules of synthetic and natural origin	39
Renal cell carcinoma therapy: Current and new drug candidates	38
Corrigendum to “Therapeutic potential of fucosyltransferases in cancer and recent development of targeted inhibitors” [Drug Discov. Today 28(1) (2023) 103394]	38
Transforming patient engagement in clinical trials: Moving from a transactional relationship to human-centered care	38
The Unitary Patent and UPC – Implications for the pharmaceutical sector	38
Computational resources in the management of antibiotic resistance: Speeding up drug discovery	38
Real-world data in drug development strategies for orphan drugs: Tafasitamab in B-cell lymphoma, a case study for an approval based on a single-arm combination trial	38
Neurotrophin peptidomimetics for the treatment of neurodegenerative diseases	38
Strategizing the human microbiome for small molecules: Approaches and perspectives	38
Artificially engineered bacteria to treat gastrointestinal disease and cancer	37
Metabophore-mediated retro-metabolic (‘MeMeReMe’) approach in drug design	37
Artificial intelligence methods in kinase target profiling: Advances and challenges	37
Therapeutic targeting of the complement system in ocular disease	37
Advances in lipid-based nanoformulations for inhaled antibiotic therapy in respiratory infections	36
Targeting hepatitis B virus cccDNA levels: Recent progress in seeking small molecule drug candidates	36
Geometric deep learning methods and applications in 3D structure-based drug design	36
Corrigendum to “Role of transient receptor potential channels in the regulation of vascular tone” [Drug Discov. Today 29(7) (2024) 104051]	36
Therapeutic potential of targeting IL-17 and its receptor signaling in neuroinflammation	36
Oncological drug discovery: AI meets structure-based computational research	36
A new era for schizophrenia drug development – Lessons for the future	35
dbDNA™: An advanced platform for genetic medicines	35
Compound–protein interaction prediction by deep learning: Databases, descriptors and models	35
2023 in review: FDA approvals of new medicines	35
PROTAC technology: A new drug design for chemical biology with many challenges in drug discovery	35
The expanding repertoire of covalent warheads for drug discovery	35
Approaches to advance drug discovery for neglected tropical diseases	35
Insight into the pivotal role of signaling pathways in psoriasis pathogenesis, potential therapeutic molecules and drug delivery approaches	35
Small molecules targeting canonical transient receptor potential channels: an update	34
Does pharma R&D need a strategic reset? Adapting to a changing US landscape	34
Operational and path dependencies impede the feasibility of hospital-based production of individually engineered drugs	34
Science of, and insights into, thermodynamic principles for dermal formulations	34
Innovation testbeds as enabling ecosystems driving nanopharmaceuticals to market	34
Recent advances in flavonoid-based nanocarriers as an emerging drug delivery approach for cancer chemotherapy	33
Nanoformulations of chemotherapeutic activators of the cGAS–STING pathway in tumor chemoimmunotherapy	33
Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236	33
Molecular medicinal insights into scaffold hopping-based drug discovery success	33
Druggable genome special issue: An introduction	33
Regulatory oversight on the use of experimental therapies during a pandemic: The case of early access to convalescent plasma therapy in three LMICs	32
Expanding therapeutic potential of Bdellovibrio bacteriovorus against multidrug-resistant pathogens	32
Death ligand receptor (DLR) signaling: Its non-apoptotic functions in cancer and the consequences of DLR-directed therapies	32
Peptide-derived ligands for the discovery of safer opioid analgesics	32
Harnessing G-quadruplex ligands for lung cancer treatment: A comprehensive overview	32
Contents page	32
Corrigendum to “Pharmacological modulation of autophagy for epilepsy therapy: Opportunities and obstacles” [Drug Discov. Today 28(6) (2023) 103600]	32
How health technology assessment can help to address challenges in drug repurposing: a conceptual framework	32
Challenges and opportunities in the discovery, development, and commercialization of pathogen-targeted antibiotics	32
Corrigendum to “Critical path activities in clinical trial setup & conduct – How to avoid bottlenecks and accelerate clinical trials” [Drug Discov. Today 28(10) (2023) 103733]	32
The importance of a go-to-market strategy in the commercialisation of cellular immunotherapies	32
A retrospective regulatory analysis of FDA recalls carried out by pharmaceutical companies from 2012 to 2023	32
Harnessing personalized tailored medicines to digital-based data-enriched edible pharmaceuticals	32
Targeting autophagy in colorectal cancer: An update on pharmacological small-molecule compounds	32
Publisher’s Note	31
A pipeline analysis of advanced therapy medicinal products	31
RhoA activation-mediated vascular permeability in capillary malformation-arteriovenous malformation syndrome: a hypothesis	31
Advancing ocular gene therapy: a machine learning approach to enhance delivery, uptake and gene expression	31

‘Home inspections’ for life sciences companies going public before clinical proof-of-concept	31
Competition of regulatory ecosystems in approving medicines: policy implications in the case of Europe	30
IdopNetwork as a genomic predictor of drug response	30
Orphan GPR52 as an emerging neurotherapeutic target	30
Using computers to ESKAPE the antibiotic resistance crisis	30
Translating precision medicine for autism spectrum disorder: A pressing need	30
Drugging the entire human proteome: Are we there yet?	30
Deadly interactions: Synergistic manipulations of concurrent pathogen infections potentially enabling future pandemics	30
Machine learning and natural language processing in clinical trial eligibility criteria parsing: a scoping review	30
Spare and repair the gut microbiota from antibiotic-induced dysbiosis: state-of-the-art	30
Regulating NETosis: An emerging facet of statin pleiotropy	30
Early career researchers’ experiences in drug discovery in Africa	30
Effectiveness of histamine receptor antagonists in the treatment of histamine-driven clinical symptoms: do we have a histamine or, better, an anti-histamine problem?	30
COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease	30
Nanomedicine approaches to reduce cytokine storms in severe infections	29
Social media mining in drug development—Fundamentals and use cases	29
Nanophotonic waveguide-based sensing of circulating cell-free mitochondrial DNA: implications for personalized medicine	29
Antimicrobial and anti-biofilm activities of bio-inspired nanomaterials for wound healing applications	29
Chiral-engineered supraparticles: Emerging tools for drug delivery	29
Recent discoveries of the role of histone modifications and related inhibitors in pathological cardiac hypertrophy	29
Surface-enhanced Raman scattering biosensors for detection of oncomiRs in breast cancer	28
Opportunities and challenges of physiologically based pharmacokinetic modeling in drug delivery	28
TDP-43 protein interactome informs about perturbed canonical pathways and may help develop personalized medicine approaches for patients with TDP-43 pathology	28
Exosome-mediated PROTAC delivery for treatment of RNA viral infections and zoonosis	28
Recent progress in covalent organic frameworks for cancer therapy	28
Evaluating the performance of drug-repurposing technologies	28
ADAM10: Function insights, disease implications, and promise of therapeutic targeting	27
Therapies for Inherited Retinal Dystrophies: What is Enough?	27
Innovation in breakthrough drugs and vaccines: Development risk, patient impact, and value	27
Targeting SIRT1-regulated autophagic cell death as a novel therapeutic avenue for cancer prevention	27
A personalized pharmaco-epistatic network model of precision medicine	27
Identification of biological targets through the correlation between cell line chemosensitivity and protein expression pattern	27
Peptide modulators of cell migration: Overview, applications and future development	27
Lysine lactylation: Regulatory mechanisms, role in health and disease, and its therapeutic potential	27
Generic dry powder inhalers bioequivalence: Batch–to-batch variability insights	27
Patents, trade secrets and pricing	27
Web resources facilitate drug discovery in treatment of COVID-19	26
Trends, challenges, and success factors in pharmaceutical portfolio management: Cognitive biases in decision-making and their mitigating measures	26
Recent trends in targeted delivery of smart nanocarrier-based microbial enzymes for therapeutic applications	26
Clinical significance and potential role of trimethylamine N-oxide in neurological and neuropsychiatric disorders	26
Comparative analysis of FDA approvals by top 20 pharma companies (2014–2023)	26
Benefits of hybrid QM/MM over traditional classical mechanics in pharmaceutical systems	26
Prospects of halofuginone as an antiprotozoal drug scaffold	26
Therapeutic potential of fucosyltransferases in cancer and recent development of targeted inhibitors	26
Evaluation of the implementation effectiveness of accelerated drug marketing registration procedures in China: lessons from the 2016–2024 regulatory review	26
Recent advances in the molecular design and applications of viral RNA-targeting antiviral modalities	26
Which cryptic sites are feasible drug targets?	25
ATP-binding cassette efflux transporters and MDR in cancer	25
Can preclinical drug development help to predict adverse events in clinical trials?	25
Nanofibers as drug-delivery systems for antimicrobial peptides	25
Sustaining pharmaceutical innovation after the Inflation Reduction Act: trends in R&D spending, equity investment, and business development	25
Biopharmaceutical R&D outsourcing: Short-term gain for long-term pain?	25
Electron diffraction: Accelerating drug development	25
Integrating heterogeneous data to facilitate COVID-19 drug repurposing	25
Novel and investigational therapies for wet and dry age-related macular degeneration	25
Applications of density functional theory in COVID-19 drug modeling	25
Concepts and applications of chemical fingerprint for hit and lead screening	25
Optical tweezers for drug discovery	25
Beyond CL and VSS: A comprehensive approach to human pharmacokinetic predictions	25
A review of the efficacy of prostate cancer therapies against castration-resistant prostate cancer	25
Active pharmaceutical ingredients (APIs) in ionic liquids: An effective approach for API physiochemical parameter optimization	25
Contents page	24
Contents page	24
Integrated nanomaterials for non-invasive photothermal therapy of rheumatoid arthritis	24
The role of venom proteomics and single-domain antibodies for antivenoms: Progress in snake envenoming treatment	24
Corrigendum to ‘Synthetic lethality: a step forward for personalized medicine in cancer’ [Drug Discov. Today 25 (2020) 305–320]	24
Extrapolation: Experience gained from original biologics	24
Metallocompounds as anticancer agents against osteosarcoma	24
Dual-action potential of cationic cryptides against infections and cancers	24
Informatic challenges and advances in illuminating the druggable proteome	24
Contents page	24
How can MSI enhance our understanding of ASO distribution?	24
Statins and angiogenesis in non-cardiovascular diseases	24
How missing value imputation is confounded with batch effects and what you can do about it	24
On the pivotal role of drug discovery in sustainable EU pharma reform	23
Nanosponges: An overlooked promising strategy to combat SARS-CoV-2	23
Positron emission tomographic imaging in drug discovery	23
Illuminating the druggable genome: Pathways to progress	23
Rapid progress in neuroimaging technologies fuels central nervous system translational medicine	23
DDR1-targeted therapies: current limitations and future potential	23
Epigenetic roles of lysine-specific demethylase 1 (LSD1) in cancer metabolism	23
Treating liver cancer through arginine depletion	23
New approaches for challenging therapeutic targets	22
Pivotal role of nitrogen heterocycles in Alzheimer’s disease drug discovery	22
SET7, a lysine-specific methyl transferase: An intriguing epigenetic target to combat diabetic nephropathy	22
Brain-derived neurotrophic factor (BDNF) in perinatal depression: Side show or pivotal factor?	22
Aceclofenac and methotrexate combination therapy could influence Th1/Th17 axis to modulate rheumatoid-arthritis-induced inflammation	22
An overview of cancer drugs approved through expedited approval programs and orphan medicine designation globally between 2011 and 2020	22
Unleashing the power of generative AI in drug discovery	22
The forced swim test has poor accuracy for identifying novel antidepressants	22
Pharmaceutical nanocrystals: A promising approach for improved topical drug delivery	22
Grasping cryptic binding sites to neutralize drug resistance in the field of anticancer	22
Advantages, progress, and future trends in oral medicated jellies/gels: Focus on adherence aspects	22
Nanotechnological approaches for targeting amyloid-β aggregation with potential for neurodegenerative disease therapy and diagnosis	21
Kinase signaling as a drug target modality for regulation of vascular hyperpermeability: A case for ARDS therapy development	21